Filing Details
- Accession Number:
- 0001213900-21-008202
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-10 19:25:15
- Reporting Period:
- 2021-02-08
- Accepted Time:
- 2021-02-10 19:25:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1553643 | Relmada Therapeutics Inc. | RLMD | Pharmaceutical Preparations (2834) | 455401931 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1658369 | Maged Shenouda | C/O Relmada Therapeutics, Inc. 880 Third Avenue, 12Th Floor New York NY 10022 | Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-08 | 11,372 | $3.24 | 13,600 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-08 | 3,603 | $35.04 | 9,997 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-09 | 5,359 | $35.24 | 4,638 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-10 | 2,410 | $35.20 | 2,228 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Options to purchase common stock | Disposition | 2021-02-08 | 11,372 | $0.00 | 11,372 | $3.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 84,678 | 2017-10-20 | 2027-10-20 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.
- The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- Sales prices range from $35.00 to $35.29 per share, inclusive.
- Sales prices range from $35.00 to $35.82 per share, inclusive
- Sales prices range from $35.00 to $35.64 per share, inclusive
- The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.
- Not applicable
Billionaire Hedge Funds
